Detalles de la búsqueda
1.
Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes.
Pharmacogenomics J
; 18(3): 480-486, 2018 05 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-28786423
2.
Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01.
Pharmacogenomics J
; 16(2): 180-5, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25987243
3.
Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib.
Ann Oncol
; 26(7): 1515-7, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25922065
4.
Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes.
Clin Pharmacol Ther
; 91(4): 647-52, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22357454
Resultados
1 -
4
de 4
1
Próxima >
>>